EGFR and non-small cell lung carcinoma: In NSCLC patients treated with the EGFR inhibitor gefitinib, patients with specific in-frame indel mutations in the EGFR gene were more sensitive to gefitinib, as these mutations increase the tumor’s dependence on growth factor signaling, compared to patients without such mutations.